Driven Primarily by the Uptake of Human Genome Sciences/GlaxoSmithKline's Benlysta, the Systemic Lupus Erythematosus Drug Market Will Quadruple to More than $1.6 Billion in 2019
Advertisement
Closely Followed by Benlysta, Rituximab Will Emerge as the Market Leader in 2019, According to Findings from Decision Resources